Request a Proposal  

Pharm-Olam Blog

News

Blog Feature

Phase III | Rare & Orphan Disease | global CRO | acquired thrombotic thrombocytopenic purpura | aTTP

By: Pharm-Olam International
October 30th, 2018

Houston, Oct. 30, 2018 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.